CVRx (NASDAQ:CVRX) Announces Earnings Results, Misses Estimates By $0.02 EPS

CVRx (NASDAQ:CVRX) issued its quarterly earnings data on Thursday. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.02), FiscalAI reports. CVRx had a negative return on equity of 152.35% and a negative net margin of 84.93%. The company had revenue of $13.83 million during the quarter, compared to analysts’ expectations of $13.93 million.

Here are the key takeaways from CVRx’s conference call:

• CVRx lowered its 2026 revenue outlook to $56 million–$57 million from $58 million–$60 million, after Q3 revenue fell 6.1% year over year to $13.8 million. Q4 revenue is expected to be $11.7 million–$12.7 million.
• Reimbursement delays at UnitedHealthcare, CVRx’s largest Medicare Advantage payer, were a major drag: the 30-day approval rate for cases handled by the company fell to about 12% from a 2025 high of 83%. CVRx is appealing denials, but says the process can take months and many customer-handled denials may not be appealed.
• Physician-champion turnover and uneven sales-team experience are slowing adoption; four of nine U.S. regions are struggling to match the growth of the five more tenured regions. Management cited early improvement in team stability but said the recovery will take time.
• CVRx reported progress in coverage and clinical evidence: two written Medicare Advantage policies now cover a combined 21% of those lives, and traditional Medicare claims data showed all submitted Q1 2026 claims were paid. In the REBALANCE real-world study, the indicated-patient group had sustained functional-class improvements and improved ejection fraction through 24 months.
• CVRx ended Q3 with $58.7 million in cash and said it has at least 18 months of runway, excluding potential additional ATM proceeds. It expects 2026 operating expenses of $99 million–$101 million after cost reductions, while continuing to invest in sales and reimbursement.

CVRx Stock Down 7.0%

Shares of CVRX stock traded down $0.11 during trading hours on Thursday, hitting $1.47. 274,601 shares of the company’s stock traded hands, compared to its average volume of 516,611. The company has a quick ratio of 6.87, a current ratio of 8.04 and a debt-to-equity ratio of 2.94. The stock’s fifty day simple moving average is $2.16 and its two-hundred day simple moving average is $5.20. CVRx has a 12-month low of $1.25 and a 12-month high of $10.63. The stock has a market cap of $39.16 million, a price-to-earnings ratio of -0.74 and a beta of 0.81.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CVRX shares. Piper Sandler lowered CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a research report on Friday, August 7th. Craig Hallum downgraded CVRx from a “buy” rating to a “hold” rating and set a $4.00 price objective for the company. in a report on Friday, August 7th. Lake Street Capital lowered CVRx from a “buy” rating to a “hold” rating and lowered their price objective for the company from $14.00 to $3.50 in a research report on Friday, August 7th. Canaccord Genuity Group set a $5.00 target price on shares of CVRx in a report on Tuesday, September 22nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a report on Friday, October 30th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $4.30.

Insider Buying and Selling at CVRx

In related news, COO Brent Binkowski acquired 26,223 shares of CVRx stock in a transaction that occurred on Thursday, August 13th. The stock was bought at an average price of $2.91 per share, with a total value of $76,308.93. Following the transaction, the chief operating officer directly owned 56,514 shares in the company, valued at approximately $164,455.74. This represents a 86.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 16.60% of the stock is owned by insiders.

About CVRx

CVRx, Inc (NASDAQ: CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to activate the body’s natural nervous system pathways to help regulate cardiovascular function.

CVRx’s primary product is the Barostim system, an implantable device that delivers electrical stimulation to baroreceptors located near the carotid arteries. By influencing signals between the cardiovascular system and the brain, Barostim is intended to reduce excessive sympathetic nervous system activity and improve symptoms and function in certain patients with heart failure.